Amunix Pharmaceuticals Overview
- Founded
- 2006
- Status
- Acquired/Merged
- Employees
- 73
- Latest Deal Type
- M&A
- Financing Rounds
- 6
- Investments
- 5
Amunix Pharmaceuticals General Information
Description
Operator of a biopharmaceutical company intended to discover, design and develop novel biologics, protein and peptide therapeutics. The company's pipeline immuno-oncology products are based on its proprietary, clinically validated and innovative universal protease-releasable masking technology platform, delivering transformative T-cell engagers (TCE) and cytokine therapies for patients with cancer.
Contact Information
Website
www.amunix.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly PE-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Parent Company
Primary Office
- 2 Tower Plaza
- Suite 1100
- South San Francisco, CA 94080
- United States
+1 (650) 000-0000
Amunix Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Amunix Pharmaceuticals‘s full profile, request access.
Request a free trialAmunix Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a biopharmaceutical company intended to discover, design and develop novel biologics, protein and peptide th
Drug Discovery
South San Francisco, CA
73
As of 2021
00000
0.000
0000-00-00
000000&0
00000
0000000
labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris ni
0000000000000
New York, NY
00
As of 0000
00000
00000000
00000
00000000
is nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dol
0000000000000
San Francisco, CA
000
As of 0000
00000
0.000
0000-00-00
000000&0
00000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialAmunix Pharmaceuticals Competitors (62)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mustang Bio | Corporation | New York, NY | 00 | 00000 | 00000000 | 00000 |
| 000000000 00000000 | Formerly VC-backed | San Francisco, CA | 000 | 00000 | 000000&0 | 00000 |
| 00000 000000000000 | Private Equity-Backed | Ahmedabad, India | 00000 | 000.00 | 000000 - 000 | 000.00 |
| 000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Boston, MA | 00 | 00000 | 00000000 | 00000 |
Amunix Pharmaceuticals Patents
Amunix Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210054077-A1 | Cd3 antigen binding fragments and compositions comprising same | Pending | 26-Jun-2019 | 000000000 | |
| JP-2021507706-A | Release segment and binding composition containing it | Pending | 21-Dec-2017 | 000000000 | |
| CA-3085950-A1 | Release segments and binding compositions comprising same | Pending | 21-Dec-2017 | 00000000000 | |
| US-20200385469-A1 | Release segments and binding compositions comprising same | Pending | 21-Dec-2017 | 00000000000 | |
| EP-3728326-A1 | Release segments and binding compositions comprising same | Pending | 21-Dec-2017 | C07K16/2809 |
Amunix Pharmaceuticals Executive Team (11)
Amunix Pharmaceuticals Board Members (13)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000 000 00.0 | Amunix Pharmaceuticals | Chief Executive Officer & Board Member | 000 0000 |
| 00000 0000000 00.0 | Self | Board Member | 000 0000 |
| 00000 000000 00.0 | Longitude Capital | Board Member | 000 0000 |
| 00000 00000 00 | Frazier Healthcare Partners | Board Member | 000 0000 |
| 00000 000000 00.0 | Frazier Healthcare Partners | Board Member | 000 0000 |
Amunix Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialAmunix Pharmaceuticals Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore Amunix Pharmaceuticals‘s full profile, request access.
Request a free trialAmunix Pharmaceuticals Investments (5)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000000 | 08-Oct-2013 | 00000 0000 | 0000 | Biotechnology | 000000 00 |
| 0000000 00000 | 16-Feb-2011 | 00000 0000 | 00000 | Pharmaceuticals | 000000 00 |
| 000000000 | 16-Feb-2011 | 00000 0000 | 0000 | Biotechnology | 000000 00 |
| 000000000 | 02-Jun-2009 | 00000 0000 | 0000 | Biotechnology | 000000 00 |
| Versartis | 01-Dec-2008 | Joint Venture | Biotechnology | 000000 00 |
Amunix Pharmaceuticals Exits (5)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 000000000 | 08-Oct-2013 | 00000 00000 00 | 0000 | Completed |
|
| 0000000 0000000000 | 16-Feb-2011 | 00000 00000 00 | 00000 | Completed |
|
| 000000000 | 16-Feb-2011 | 00000 00000 00 | 0000 | Completed |
|
| 000000000 | 02-Jun-2009 | 00000 00000 00 | 0000 | Completed |
|
| Versartis | 01-Dec-2008 | Joint Venture | Completed |
|